![IJMS | Free Full-Text | Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control IJMS | Free Full-Text | Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control](https://www.mdpi.com/ijms/ijms-22-04374/article_deploy/html/images/ijms-22-04374-g002.png)
IJMS | Free Full-Text | Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control
![SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats | American Journal of Physiology-Renal Physiology SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats | American Journal of Physiology-Renal Physiology](https://journals.physiology.org/cms/10.1152/ajprenal.00053.2022/asset/images/medium/f-00053-2022r01.png)
SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats | American Journal of Physiology-Renal Physiology
![Tips for Starting an SGLT2 Inhibitor to Treat Your Heart Failure – Worksheet | CardioSmart – American College of Cardiology Tips for Starting an SGLT2 Inhibitor to Treat Your Heart Failure – Worksheet | CardioSmart – American College of Cardiology](https://www.cardiosmart.org/images/default-source/assets-images/worksheets/sglt2i-checklist.jpg?sfvrsn=9862235c_1)
Tips for Starting an SGLT2 Inhibitor to Treat Your Heart Failure – Worksheet | CardioSmart – American College of Cardiology
![Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality | npj Aging Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality | npj Aging](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41514-017-0012-0/MediaObjects/41514_2017_12_Fig1_HTML.jpg)
Treatment of diabetic mice with the SGLT2 inhibitor TA-1887 antagonizes diabetic cachexia and decreases mortality | npj Aging
![Cureus | A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis | Article Cureus | A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis | Article](https://assets.cureus.com/uploads/figure/file/449060/article_show_b92f8d002dc211edac1ae73769e58c06-khyati-research-figure-1.webp)
Cureus | A Literature Review of the Therapeutic Perspectives of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor-Induced Euglycemic Diabetic Ketoacidosis | Article
![SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats | American Journal of Physiology-Renal Physiology SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats | American Journal of Physiology-Renal Physiology](https://journals.physiology.org/cms/10.1152/ajprenal.00070.2022/asset/images/medium/f-00070-2022r01.png)
SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats | American Journal of Physiology-Renal Physiology
![Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway](https://www.e-dmj.org/upload//thumbnails/dmj-2020-0187f7.jpg)
Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway
![Schematic representation of the clinical effects of SGLT2 inhibitor.... | Download Scientific Diagram Schematic representation of the clinical effects of SGLT2 inhibitor.... | Download Scientific Diagram](https://www.researchgate.net/publication/284347016/figure/fig3/AS:506987533094924@1497886655925/Schematic-representation-of-the-clinical-effects-of-SGLT2-inhibitor-Irrespective-of-the.png)
Schematic representation of the clinical effects of SGLT2 inhibitor.... | Download Scientific Diagram
![Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features ... Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features ...](https://jpet.aspetjournals.org/content/jpet/358/1/94/F1.large.jpg)
Interaction of the Sodium/Glucose Cotransporter (SGLT) 2 Inhibitor Canagliflozin with SGLT1 and SGLT2: Inhibition Kinetics, Sidedness of Action, and Transporter-Associated Incorporation Accounting for its Pharmacodynamic and Pharmacokinetic Features ...
![SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control | Nature Reviews Cardiology SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control | Nature Reviews Cardiology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41569-020-0406-8/MediaObjects/41569_2020_406_Fig1_HTML.png)
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control | Nature Reviews Cardiology
![Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy - ScienceDirect Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0003986121002447-ga1.jpg)
Swertisin, a novel SGLT2 inhibitor, with improved glucose homeostasis for effective diabetes therapy - ScienceDirect
![How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? | Arteriosclerosis, Thrombosis, and Vascular Biology How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes? | Arteriosclerosis, Thrombosis, and Vascular Biology](https://www.ahajournals.org/cms/asset/e379c42b-ab84-4702-a53a-fc55a81b7ca8/atvbaha.119.311904ga1.jpg)